REAL-WORLD EFFICACY, SAFETY, AND DRUG SURVIVAL OF IL-23 INHIBITORS IN OVERWEIGHT AND OBESE PATIENTS WITH PSORIASIS: A 52-WEEK RETROSPECTIVE STUDY

Gizem Pehlivan ULUTAS, Yavuz SEMIZ

The Medical Bulletin of Haseki - 2026;64(4):345-353

University of Health Sciences Türkiye, Istanbul Haseki Training and Research Hospital, Clinic of Dermatology and Venereology, Istanbul, Türkiye

 

Aim: Obesity is a common comorbidity in psoriasis and has been associated with reduced response to biologic therapies. However, data on the real-world effectiveness of interleukin (IL)-23 inhibitors in overweight and obese patients with psoriasis remain limited. This study aimed to evaluate the efficacy, safety, and drug survival of IL-23 inhibitors in this patient population over 52 weeks. Methods: This retrospective, single-center observational study included patients with psoriasis and a body mass index (BMI) >=25 kg/m2 who were treated with guselkumab or risankizumab between November 2021 and November 2025. Efficacy was assessed using absolute Psoriasis Area and Severity Index (PASI) scores and PASI75/90/100 response rates at predefined time points. Drug survival, adverse events, and reasons for discontinuation were evaluated. Multivariable logistic regression analysis was performed to identify independent predictors of achieving PASI90 at week 52. Results: Among the 75 included patients, the mean PASI score at baseline was 13.7+/-7.7, which improved to 0.8+/-1.1 at week 52. Psoriasis Area and Severity Index 90 and PASI100 response rates increased from 37.3% and 12.0% at weeks 12-16 to 77.5% and 56.3% at week 52, respectively. Overweight patients achieved significantly higher PASI90 response rates than obese patients at weeks 28 and 52. In multivariable analysis, lower BMI and biologic-naïve status remained independent predictors of achieving PASI90 at week 52. The 52-week drug survival rate was 94.7%. Treatment was discontinued in 4 patients (5.3%), most commonly because of secondary loss of response. The most common adverse events were infections. No cases of hepatitis B or tuberculosis reactivation were observed. Conclusion: Interleukin-23 inhibitors demonstrated sustained clinical effectiveness, high 52-week drug survival, and a favorable safety profile in overweight and obese patients with psoriasis. Although lower BMI was independently associated with higher odds of achieving PASI90 by week 52, drug survival remained comparable across BMI groups, supporting the use of IL-23 inhibitors in clinical practice.